Investing
GSK sues Pfizer in US for patent infringement over RSV vaccine
© Reuters. FILE PHOTO: A compagny logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron/File Photo
2/3
By Blake Brittain
(Reuters) – British biopharmaceutical giant GSK sued Pfizer (NYSE:) in Delaware federal court on Wednesday, accusing Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo of violating GSK’s patent rights in its rival RSV shot Arexvy.
GSK said Pfizer’s vaccine infringes four of its patents related to the antigen its shots use to fight the respiratory disease. Both vaccines were approved for use in adults over 60 by the U.S. Food and Drug Administration in May.
Read the full article here
-
Investing6 days ago
Hurricane Helene Hits Spruce Pine Mine, Quartz Used for Tech
-
Side Hustles7 days ago
5 Key Strategies for a Seamless Cloud Migration
-
Investing7 days ago
Israel stocks lower at close of trade; TA 35 down 0.23% By Investing.com
-
Side Hustles6 days ago
VP Exec’s Top Tips for Negotiating and Relationship-Building
-
Passive Income7 days ago
Go Paperless with the PDF Reader Pro for $49.99
-
Side Hustles7 days ago
Why the Future of Cybersecurity Marketing Relies on Trust
-
Side Hustles6 days ago
Why the Smallest Details Mean the Most in Marketing
-
Make Money5 days ago
The Top Employers and Opportunities for Part-Time Remote Jobs